ANG 2002
Alternative Names: ANG-2002Latest Information Update: 23 Oct 2022
At a glance
- Originator AngioChem
- Class Analgesics; Neuropeptides; Peptide drug conjugates
- Mechanism of Action Neurotensin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Pain
Most Recent Events
- 12 Sep 2022 ANG 2002 is available for licensing as of 12 Sep 2022. http://angiochem.com/partnering
- 12 Sep 2022 Preclinical trials in Pain in Canada (Intracarotid) (AngioChem website, September 2022)
- 12 Sep 2022 Pharmacodynamics data from preclinical trials in Pain released by AngioChem (AngioChem website, September 2022)